Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo.
The in vivo effect of sertraline on oxidative drug metabolism mediated by cytochrome P450 (CYP) 3A was assessed by coadministration with alprazolam, carbamazepine, and terfenadine in three separate studies. Sertraline at doses of 50 to 200 mg/day for 10 to 20 days did not alter the pharmacokinetics of these CYP3A substrates/drugs.
Preskorn
S H
SH
Psychiatric Research Institute, Wichita, KS 67214, USA.
Alderman
J
J
Greenblatt
D J
DJ
Horst
W D
WD
D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D000525:Alprazolam / Q000493:pharmacokinetics; D001189:Aryl Hydrocarbon Hydroxylases; D001711:Biotransformation / Q000187:drug effects; D002220:Carbamazepine / Q000493:pharmacokinetics; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D006801:Humans; D008297:Male; D008875:Middle Aged; D010089:Oxidoreductases, N-Demethylating / Q000037:antagonists & inhibitors*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D020280:Sertraline; D013379:Substrate Specificity; D016593:Terfenadine / Q000493:pharmacokinetics
D015057:1-Naphthylamine; D000525:Alprazolam; D001189:Aryl Hydrocarbon Hydroxylases; D002220:Carbamazepine; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D010089:Oxidoreductases, N-Demethylating; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D016593:Terfenadine